Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Acumen Pharmaceuticals Inc
ABOSCurrent price
1.56 USD
-0.05 USD (-3.11%)
Last closed
1.59 USD
Company
www.acumenpharm.com
ISIN
US00509G2093
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
118 357 208 USD
Yield for 12 month
-57.02 %
1Y
3Y
5Y
10Y
15Y
ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Address: 427 Park Street, Charlottesville, VA, United States, 22902
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.80 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-42 318 000 USD
Last Year
-169 000 USD
Current Quarter
–
Last Quarter
-45 000 USD
Key Figures ABOS
1 year
3 years
5 years
10 years
EBITDA
-92 838 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-20.99 %
PEG Ratio
–
Return On Equity TTM
-32.83 %
Wall Street Target Price
10.80 USD
Revenue TTM
329 000 USD
Book Value
3.62 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-32 361 000 USD
Earnings per share
-1.38 USD
Diluted Eps TTM
-1.38 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ABOS
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History ABOS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ABOS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
89.67
Price Sales TTM
538.78
Enterprise Value EBITDA
-0.60
Price Book MRQ
0.54
Financials ABOS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ABOS
For 52 weeks
1.91 USD
5.09 USD
50 Day MA
2.53 USD
Shares Short Prior Month
1 466 462
200 Day MA
2.96 USD
Short Ratio
6.61
Shares Short
1 385 196
Short Percent
3.10 %
BeatStart